Elanco Animal Health (NYSE:ELAN) Updates FY 2025 Earnings Guidance

Key Points

• Elanco Animal Health has provided its FY 2025 earnings guidance, projecting earnings per share between $0.850 and $0.910, which exceeds the consensus estimate of $0.840.
• The company's revenue guidance for FY 2025 is set at $4.6 billion, surpassing the consensus estimate of $4.5 billion.
• Analysts have updated their ratings for Elanco, with several upgrading the stock to "buy" or "outperform," leading to a consensus price target of $16.17.

Elanco Animal Health (NYSE:ELAN - Get Free Report) issued an update on its FY 2025 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of 0.850-0.91 for the period, compared to the consensus estimate of 0.840. The company issued revenue guidance of $4.6 billion-$4.6 billion, compared to the consensus revenue estimate of $4.5 billion. Elanco Animal Health also updated its Q3 2025 guidance to 0.120-0.160 EPS.

Analyst Ratings Changes

Several research firms have weighed in on ELAN. UBS Group boosted their target price on shares of Elanco Animal Health from $18.00 to $19.00 and gave the company a "buy" rating in a research note on Friday. William Blair raised Elanco Animal Health from a "market perform" rating to an "outperform" rating in a report on Thursday, June 26th. Stifel Nicolaus boosted their target price on Elanco Animal Health from $16.00 to $17.00 and gave the stock a "buy" rating in a research report on Wednesday, July 2nd. Wall Street Zen upgraded Elanco Animal Health from a "hold" rating to a "buy" rating in a research note on Saturday, July 5th. Finally, Leerink Partnrs raised Elanco Animal Health from a "hold" rating to a "strong-buy" rating in a report on Thursday, July 17th. Two equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $17.33.

Elanco Animal Health Stock Up 1.8%

Shares of Elanco Animal Health stock traded up $0.31 during trading hours on Monday, hitting $16.98. The company had a trading volume of 4,226,663 shares, compared to its average volume of 5,408,638. The company has a market cap of $8.43 billion, a P/E ratio of 19.78, a price-to-earnings-growth ratio of 3.12 and a beta of 1.66. The company's 50-day moving average is $14.32 and its two-hundred day moving average is $12.08. The company has a debt-to-equity ratio of 0.61, a current ratio of 2.60 and a quick ratio of 1.40. Elanco Animal Health has a twelve month low of $8.02 and a twelve month high of $17.29.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported $0.26 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.20 by $0.06. The firm had revenue of $1.24 billion during the quarter, compared to the consensus estimate of $1.19 billion. Elanco Animal Health had a net margin of 9.68% and a return on equity of 7.04%. Elanco Animal Health's revenue was up 4.8% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.30 earnings per share. Analysts anticipate that Elanco Animal Health will post 0.91 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Elanco Animal Health

Hedge funds have recently added to or reduced their stakes in the company. Empowered Funds LLC raised its stake in shares of Elanco Animal Health by 35.2% during the 1st quarter. Empowered Funds LLC now owns 15,835 shares of the company's stock worth $166,000 after purchasing an additional 4,121 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in Elanco Animal Health by 4.5% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,793,337 shares of the company's stock valued at $18,830,000 after acquiring an additional 76,408 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in Elanco Animal Health during the 1st quarter worth $2,065,000. Finally, Goldman Sachs Group Inc. grew its position in shares of Elanco Animal Health by 104.5% during the 1st quarter. Goldman Sachs Group Inc. now owns 4,787,394 shares of the company's stock worth $50,268,000 after purchasing an additional 2,445,872 shares in the last quarter. Institutional investors and hedge funds own 97.48% of the company's stock.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.